12:00 AM
 | 
Jul 01, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Dulaglutide: Additional Phase III data

Additional data from the double-blind, international Phase III AWARD-3 trial in 807 patients with early Type II diabetes showed that once-weekly 0.75 mg dulaglutide reduced mean HbA1c from baseline to week 26, the primary endpoint, by 0.71% and once-weekly 1.5 mg dulaglutide reduced mean HbA1c from baseline to week 26 by 0.78% vs. 0.56% for metformin (p<0.025 for both for superiority). Additionally, a significantly greater proportion of patients receiving low- and high-dose dulaglutide achieved an HbA1c of <7% at week 26 vs. metformin (62.6% and...

Read the full 405 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >